Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Statin Effect on Arrhythmogenic Cardiomyopathy Progression
2024-514643-28-00Phase 2Authorised
- Sponsor
- Centro Cardiologico Monzino
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of atorvastatin in arrhythmogenic cardiomyopathy (ACM), sponsored by Centro Cardiologico Monzino. Primary endpoint: Deterioration from baseline of RV free wall longitudinal strain measured by echocardiography. Planned start Oct 2024; status: authorised.
02
Drugs
atorvastatin
03
Conditions
arrhythmogenic cardiomyopathy (ACM)
Beyond the preview
Go deeper on 2024-514643-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514643-28-00.